Canaan Valuation
Is CAN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CAN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CAN ($1.97) is trading below our estimate of fair value ($8.17)
Significantly Below Fair Value: CAN is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CAN?
Key metric: As CAN is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is CAN's PS Ratio? | |
|---|---|
| PS Ratio | 2.5x |
| Sales | US$229.63m |
| Market Cap | US$566.85m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.3x |
| Enterprise Value/EBITDA | -3x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does CAN's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.7x | ||
CRSR Corsair Gaming | 0.6x | 10.2% | US$772.7m |
KODK Eastman Kodak | 0.4x | n/a | US$423.7m |
HEAR Turtle Beach | 1x | 14.7% | US$316.9m |
PMTS CPI Card Group | 0.7x | 7.9% | US$332.0m |
CAN Canaan | 2.5x | 43.8% | US$566.8m |
Price-To-Sales vs Peers: CAN is expensive based on its Price-To-Sales Ratio (2.5x) compared to the peer average (0.7x).
Price to Sales Ratio vs Industry
How does CAN's PS Ratio compare vs other companies in the US Tech Industry?
Price-To-Sales vs Industry: CAN is expensive based on its Price-To-Sales Ratio (2.5x) compared to the US Tech industry average (1x).
Price to Sales Ratio vs Fair Ratio
What is CAN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 2.5x |
| Fair PS Ratio | 0.1x |
Price-To-Sales vs Fair Ratio: CAN is expensive based on its Price-To-Sales Ratio (2.5x) compared to the estimated Fair Price-To-Sales Ratio (0.1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$1.97 | US$2.47 +25.5% | 21.5% | US$3.00 | US$1.89 | n/a | 4 |
| Nov ’25 | US$1.25 | US$2.48 +98.6% | 21.3% | US$3.02 | US$1.92 | n/a | 4 |
| Oct ’25 | US$0.97 | US$3.68 +279.7% | 48.3% | US$6.68 | US$2.00 | n/a | 4 |
| Sep ’25 | US$0.92 | US$4.80 +420.5% | 37.5% | US$6.60 | US$3.00 | n/a | 2 |
| Aug ’25 | US$0.98 | US$4.74 +385.1% | 37.1% | US$6.50 | US$2.98 | n/a | 2 |
| Apr ’25 | US$1.40 | US$2.75 +96.4% | 9.1% | US$3.00 | US$2.50 | n/a | 2 |
| Mar ’25 | US$1.63 | US$2.75 +68.7% | 9.1% | US$3.00 | US$2.50 | n/a | 2 |
| Feb ’25 | US$1.38 | US$4.24 +207.4% | 29.4% | US$5.49 | US$2.99 | n/a | 2 |
| Jan ’25 | US$2.31 | US$4.24 +83.7% | 29.4% | US$5.49 | US$2.99 | n/a | 2 |
| Dec ’24 | US$1.59 | US$4.99 +213.9% | 29.2% | US$6.46 | US$3.01 | n/a | 3 |
| Nov ’24 | US$1.80 | US$5.27 +192.7% | 18.1% | US$6.31 | US$4.00 | US$1.25 | 3 |
| Oct ’24 | US$1.82 | US$5.27 +189.4% | 18.1% | US$6.31 | US$4.00 | US$0.97 | 3 |
| Sep ’24 | US$1.99 | US$5.27 +164.7% | 18.1% | US$6.31 | US$4.00 | US$0.92 | 3 |
| Aug ’24 | US$3.15 | US$5.33 +69.1% | 19.2% | US$6.49 | US$4.00 | US$0.98 | 3 |
| Jul ’24 | US$2.13 | US$5.33 +150.1% | 19.2% | US$6.49 | US$4.00 | US$1.03 | 3 |
| Jun ’24 | US$1.95 | US$5.33 +173.2% | 19.2% | US$6.49 | US$4.00 | US$1.01 | 3 |
| May ’24 | US$2.75 | US$6.53 +137.5% | 31.9% | US$9.11 | US$4.00 | US$0.87 | 3 |
| Apr ’24 | US$2.70 | US$6.53 +141.9% | 31.9% | US$9.11 | US$4.00 | US$1.40 | 3 |
| Mar ’24 | US$2.78 | US$7.51 +170.1% | 32.2% | US$9.24 | US$4.09 | US$1.63 | 3 |
| Feb ’24 | US$3.31 | US$7.01 +111.9% | 30.3% | US$9.03 | US$4.00 | US$1.38 | 4 |
| Jan ’24 | US$2.06 | US$7.01 +240.5% | 30.3% | US$9.03 | US$4.00 | US$2.31 | 4 |
| Dec ’23 | US$2.52 | US$7.01 +178.3% | 30.3% | US$9.03 | US$4.00 | US$1.59 | 4 |
| Nov ’23 | US$3.02 | US$7.66 +153.5% | 20.8% | US$8.88 | US$5.00 | US$1.80 | 4 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Diebold Nixdorf
US$1.7b
Engages in the automating, digitizing, and transforming the way people bank and shop worldwide.
DBD
US$45.69
7D
12.6%
1Y
83.9%
Avnet
US$4.7b
Distributes electronic component technology.
AVT
US$54.45
7D
2.6%
1Y
15.3%
Gauzy
US$147.5m
An integrated light and vision control company, develops, manufactures, and supplies liquid crystal controllers and films in Israel, the United States, Europe, France, Asia, and internationally.
GAUZ
US$7.89
7D
10.0%
1Y
n/a